Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03366272 | Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients(NIVEAU) | completed | Phase 2 / Phase 3 | 348 | Universität des SaarlandesOTHER | 8 | Jan 28, 2025 | clinicaltrials |
| NCT03263026 | Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | completed | Phase 3 | 256 | Denovo Biopharma LLCINDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | active not recruiting | Phase 3 | 236 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02990338 | Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients(ICARIA-MM) | completed | Phase 3 | 307 | SanofiINDUSTRY | 24 | Jan 17, 2025 | clinicaltrials |
| NCT02997202 | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | completed | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 16 | Jan 17, 2025 | clinicaltrials |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 / Phase 3 | 76 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT00769522 | FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | completed | Phase 3 | 564 | German CLL Study GroupOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT02863718 | Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression(CLL12) | completed | Phase 3 | 515 | German CLL Study GroupOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT06363994 | A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL | recruiting | Phase 3 | 476 | InnoCare Pharma Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06740916 | Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance | recruiting | Phase 3 | 240 | Siriraj HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05477589 | Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML(SCRIPT-AML) | recruiting | Phase 3 | 170 | Vastra Gotaland RegionOTHER_GOV | 10 | Dec 19, 2024 | clinicaltrials |
| NCT06742138 | To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma | not yet recruiting | Phase 3 | 284 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 19, 2024 | clinicaltrials |
| NCT06561854 | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone(FREEDOM) | recruiting | Phase 3 | 318 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 727 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Dec 13, 2024 | clinicaltrials |
| NCT02612311 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia(UNITY-CLL) | terminated | Phase 3 | 603 | TG Therapeutics, Inc.INDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT01228331 | Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL | completed | Phase 2 / Phase 3 | 745 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02626455 | Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)(CHRONOS-4) | terminated | Phase 3 | 551 | BayerINDUSTRY | 35 | Dec 11, 2024 | clinicaltrials |
| NCT05665140 | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients(ELIAS) | recruiting | Phase 2 / Phase 3 | 100 | University Hopsital Schleswig Holstein Campus LübeckOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03836014 | Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma(CONFIRM) | active not recruiting | Phase 3 | 436 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06588413 | Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan(FONDO-LOW) | recruiting | Phase 3 | 172 | Augusta UniversityOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02406092 | Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | completed | Phase 3 | 139 | Hoffmann-La RocheINDUSTRY | 3 | Nov 21, 2024 | clinicaltrials |
| NCT02181413 | A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant | completed | Phase 3 | 656 | TakedaINDUSTRY | 33 | Nov 19, 2024 | clinicaltrials |
| NCT04168502 | Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | recruiting | Phase 3 | 414 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT04655092 | Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients | recruiting | Phase 3 | 67 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06002490 | A Study to Evaluate P1101 in Japanese PV Patients | completed | Phase 3 | 21 | PharmaEssentia Japan K.K.INDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01093196 | Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients | completed | Phase 3 | 660 | Fondazione EMN Italy OnlusOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04934475 | MInimal Residual Disease Adapted Strategy(MIDAS) | active not recruiting | Phase 3 | 791 | Intergroupe Francophone du MyelomeNETWORK | 3 | Nov 7, 2024 | clinicaltrials |
| NCT01091831 | Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects | completed | Phase 3 | 389 | Fondazione EMN Italy OnlusOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) | terminated | Phase 3 | 82 | MEI Pharma, Inc.INDUSTRY | 19 | Nov 4, 2024 | clinicaltrials |
| NCT03053440 | A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)(ASPEN) | completed | Phase 3 | 201 | BeiGeneINDUSTRY | 12 | Oct 26, 2024 | clinicaltrials |
| NCT01503515 | Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant | completed | Phase 3 | 292 | Children's Oncology GroupNETWORK | 2 | Oct 16, 2024 | clinicaltrials |
| NCT03595800 | Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen(HaploMUD-RIC) | completed | Phase 3 | 9 | Institut Paoli-CalmettesOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT05177731 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML | active not recruiting | Phase 3 | 188 | Chen SuningOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)(HL-Russia-1) | recruiting | Phase 3 | 300 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaOTHER | 2 | Sep 27, 2024 | clinicaltrials |
| NCT06613035 | Twice-per-weekSelinexor, 2 Days Melphalan | not yet recruiting | Phase 3 | 126 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT00004112 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma | completed | Phase 3 | — | University of NebraskaOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia(BBClean) | recruiting | Phase 2 / Phase 3 | 90 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 269 | Pharmacyclics LLC.INDUSTRY | 16 | Sep 19, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT03078855 | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma(ILyAD) | completed | Phase 3 | 211 | Jonathan FriedbergOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02920008 | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | completed | Phase 3 | 302 | Astex Pharmaceuticals, Inc.INDUSTRY | 15 | Aug 28, 2024 | clinicaltrials |
| NCT02348489 | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | completed | Phase 3 | 815 | Astex Pharmaceuticals, Inc.INDUSTRY | 24 | Aug 27, 2024 | clinicaltrials |
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | completed | Phase 3 | 417 | Astex Pharmaceuticals, Inc.INDUSTRY | 14 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT06573645 | A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL | not yet recruiting | Phase 3 | 428 | Xia YiOTHER | 0 | Aug 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2025source: clinicaltrials